Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Massachusetts General Hospital · HIV-1-infection · Frailty
Phase 2
Recruiting
100
2026-05
Evidence dashboardStudies since 2002Updated Jul 31, 2026
TesamorelinClinical Trials.
A source-linked view of every Tesamorelin study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 24
- Recruiting
- 3
- Completed
- 14
- Terminated
- 4
- Results posted
- 10
- Average enrollment
- 79
- Countries
- 7
- Highest phase
- Phase 4
Largest indexed study
412 participants · NCT00123253 →Developer / research origin
Theratechnologies
Evidence summary
Activity is not efficacy.
Tesamorelin appears in 24 indexed studies: 3 recruiting, 14 completed and 10 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Tesamorelin is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Hudson Biotech · Metabolic Associated Steatotic Liver Disease · Nonalcoholic Steatohepatitis
Phase 2
Recruiting
120
2026-03
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Johns Hopkins University · Peripheral Nerve Injuries
Phase 2
Recruiting
36
2025-11
NCT IDStudyPhase / statusEnrollmentUpdated
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
University of California, San Diego · Mild Cognitive Impairment
Phase 2
Completed
73
2026-03
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Massachusetts General Hospital · Non-Alcoholic Fatty Liver Disease · Obesity
Phase 2
Completed
51
2025-11
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Theratechnologies · Lipodystrophy · HIV Infections
Phase 3
Completed
263
2022-09
Growth Hormone Dynamics and Cardiac Steatosis in HIV
Massachusetts General Hospital · Human Immunodeficiency Virus · Lipodystrophy
Not applicable
Completed
23
2022-07
Tesamorelin Effects on Liver Fat and Histology in HIV
Massachusetts General Hospital · Human Immunodeficiency Virus (HIV) · Nonalcoholic Fatty Liver Disease (NAFLD)
Not applicable
Completed
61
2020-01
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
The University of Texas Medical Branch, Galveston · Mild Cognitive Impairment
Phase 1
Completed
22
2019-11
Showing 6 of 14 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Body Composition and Adipose Tissue in HIV
Columbia University · HIV Lipodystrophy Syndrome · Growth Hormone Deficiency
Phase 4
Terminated
6
2026-05
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
Theratechnologies · Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Terminated
3
2022-03
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
National Institute of Nursing Research (NINR) · Sleep Disorder · Traumatic Brain Injury
Phase 2
Withdrawn
0
2019-11
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Theratechnologies · HIV
Not applicable
Terminated
391
2018-09
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Theratechnologies · Diabetic Retinopathy · HIV
Phase 4
Terminated
129
2018-09
Egrifta Replacement and Sleep Disordered Breathing
Johns Hopkins University · Lipodystrophy
Not applicable
Withdrawn
0
2017-03
Showing 6 of 7 studies
Full study index
Search Tesamorelin trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
24 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 42419889 ↗Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, Walpert AR, Galdamez ME, Zorgno I, Foldyna B, Jarraya M, Reusch JE, Lee H, Grinspoon SK, Jankowski CM, Fourman LT. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026 Jul 8;16(7):e120740. doi: 10.1136/bmjopen-2026-120740.Linked from NCT06554717PMID 28832410 ↗Fourman LT, Czerwonka N, Feldpausch MN, Weiss J, Mamputu JC, Falutz J, Morin J, Marsolais C, Stanley TL, Grinspoon SK. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS. 2017 Oct 23;31(16):2253-2259. doi: 10.1097/QAD.0000000000001614.Linked from NCT00608023PMID 22495074 ↗Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.Linked from NCT00608023PMID 20554713 ↗Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.Linked from NCT00608023PMID 20101189 ↗Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.Linked from NCT00608023PMID 31611038 ↗Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 Dec;6(12):e821-e830. doi: 10.1016/S2352-3018(19)30338-8. Epub 2019 Oct 11.Linked from NCT02196831PMID 34006921 ↗Fourman LT, Stanley TL, Billingsley JM, Sui SJH, Feldpausch MN, Boutin A, Zheng I, McClure CM, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Chung RT, Grinspoon SK. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Sci Rep. 2021 May 18;11(1):10485. doi: 10.1038/s41598-021-89966-y.Linked from NCT02196831PMID 33852720 ↗Stanley TL, Fourman LT, Wong LP, Sadreyev R, Billingsley JM, Feldpausch MN, Zheng I, Pan CS, Boutin A, Lee H, Corey KE, Torriani M, Kleiner DE, Chung RT, Hadigan CM, Grinspoon SK. Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clin Infect Dis. 2021 Aug 16;73(4):621-630. doi: 10.1093/cid/ciab019.Linked from NCT02196831
Related pages
Keep researching Tesamorelin.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.
DatabaseTesamorelin database page →Market comparisonTesamorelin research listings →Lab reportsSearch the COA ledger →Research vendor recordAscension Peptides →Research vendor recordNura Peptide →Research vendor recordGlacier Aminos →Research vendor recordEZ Peptides →Research vendor recordNOVA Labs →Source registrySearch ClinicalTrials.gov ↗